Aortic thoracic neuromodulation in heart failure with preserved ejection fraction

Abstract

Abstract The inadequacy of medical therapies for heart failure with preserved ejection fraction (HFpEF) is driving the development of device‐based solutions targeting underlying pathophysiologic abnormalities. The maladaptive autonomic imbalance with a reduction in vagal parasympathetic activity and increased sympathetic signalling contributes to the deterioration of cardiac performance, patient fitness, and the increased overall morbidity and mortality. Thoracic aortic vagal afferents mediate parasympathetic signalling, and their stimulation has been postulated to restore autonomic balance. In this first‐in‐man experience with chronic stimulation of aortic vagal afferents (Harmony™ System, Enopace, Israel), we demonstrate improved left atrial remodelling and function parallel with improved left ventricular performance. The observed favourable structural and functional cardiac changes remained stable throughout the 1 year follow‐up and were associated with improved symptoms and physical fitness. The current experience warrants further validation of the endovascular stimulation of aortic thoracic afferents as a new interventional approach for device‐based treatment in HFpEF.

Keywords

• Aortic thoracic neuromodulation
• Heart failure with preserved ejection fraction (HFpEF)
• Autonomic imbalance
• Harmony™ system
• Enopace